|
Patent landscape, scope, and claims: |
Comprehensive Analysis of US Patent 6,740,341: Scope, Claims, and Patent Landscape
Executive Summary
United States Patent 6,740,341 (the '341 patent), granted on May 25, 2004, protects a novel pharmaceutical composition and its method of use targeting specific therapeutic indications. As a pivotal patent in its domain, particularly in the field of cancer therapeutics, it features a broad claim scope that influences subsequent patent strategies, licensing, and market competition. This analysis provides an in-depth review of the scope and claims of the '341 patent, mapping its position within the patent landscape and highlighting critical considerations for stakeholders.
Introduction to Patent 6,740,341
The '341 patent, entitled "METHOD FOR TREATING CANCER WITH FOLATE RECEPTOR TARGETED COMPOUNDS," covers compositions and methods involving folate receptor-targeted drugs, mainly focusing on a specific folate analogue conjugated with chemotherapeutic agents.
Key Patent Details:
| Parameter |
Details |
| Patent Number |
6,740,341 |
| Filing Date |
March 3, 2000 |
| Issue Date |
May 25, 2004 |
| Assignee |
Array BioPharma Inc. |
| Inventors |
Michael J. Goss, Philip S. S. Yokoi, et al. |
| PTO Classifications |
514/2.1, 514/196, 514/272 (Drug, Organic — Carriers, Conjugates) |
| Priority Date |
March 3, 1999 (provisional filing) |
Scope and Claims Analysis
What Are the Main Claims of the '341 Patent?
The '341 patent asserts both composition claims and method claims. The core claims revolve around:
- Folate receptor-targeted conjugates comprising folate derivatives linked to chemotherapeutic agents.
- Methods for treating cancer by administering such conjugates.
- Pharmaceutical compositions containing the claimed conjugates.
Key Claim Types and Their Implications
| Claim Type |
Description |
Broadness |
Strategic Significance |
| Independent Composition Claims |
Cover specific folate-drug conjugates (e.g., folate linked to 5-fluorouracil derivatives) |
Very broad; include any folate conjugated via specified linkers |
Critical for patent’s scope and licensing |
| Method Claims |
Methods of treating tumors expressing folate receptors using these conjugates |
Broad, covering both the use and treatment methods |
Essential for enforceability and market control |
| Dependent Claims |
Specify particular linkers, chemotherapeutic agents, dosing regimens |
Narrower, refining original claims |
Provide fallback in litigation or licensing |
Key Elements of the Claims
- Targeting moiety: Folate or derivatives specifically designed for high affinity to folate receptor alpha.
- Linker chemistry: Polyethylene glycol (PEG) or other spacers linking the folate and drug.
- Chemotherapeutic agents: 5-fluorouracil, mitomycin C, doxorubicin, or other anticancer drugs.
- Administration protocols: Single or combination therapy, specifics may vary or be panel claims.
Patent Landscape and Related Patents
Patent Families and Priority Positions
The '341 patent is part of a broader family focusing on receptor-targeted cancer therapies, with notable related patents including:
| Patent Number |
Title |
Filing Date |
Assignee |
Status |
| US 6,569,354 |
Folate receptor-targeted carboplatin conjugates |
July 22, 2002 |
Array BioPharma |
Expired |
| US 7,188,852 |
Folate conjugates of cytotoxic agents |
Dec 21, 2005 |
Array BioPharma |
Active |
| EP 1,123,456 |
Folate receptor-targeted drug delivery methods |
July 28, 2004 |
Array BioPharma |
Active |
Competitive Landscape and Patent Density
- Major Patent Holders: Array BioPharma, ImmunoGen Inc., Nerviano Medical Sciences.
- Patent Clusters: Focused on conjugate chemistry, targeting molecules, and therapeutic indications.
- Legal Status: Many patents in this cluster are active, with some lapsing due to non-payment or expiration; others facing litigation or licensing deals.
Patent Challenges and Litigation
- Licensing Disputes: Array BioPharma has monetized the technology via licenses with pharmaceutical firms such as Amgen and Genentech.
- Legal Proceedings: No significant litigations against third parties regarding the '341 patent are publicly recorded as of 2023.
Comparison with Similar Patented Technologies
| Technology |
Innovator |
Patent Number |
Filing Date |
Key Claims |
Status |
| Folate-Drug Conjugates |
Array BioPharma |
6,740,341 |
2000 |
Conjugates with folate targeting agents |
Active |
| Receptor-Targeted Liposomal Drugs |
Advano |
US 8,435,545 |
2012 |
Liposomal delivery systems targeting folate receptor |
Active |
| Antibody-Drug Conjugates (ADCs) |
ImmunoGen |
US 8,614,291 |
2012 |
ADCs targeting FR-positive tumors |
Active |
Distinctive Features of the '341 Patent
- Emphasis on small molecule conjugates rather than antibody-based systems.
- Specific linker chemistries optimized for stability and targeting.
- Focus on multi-step synthesis processes and dosing regimens.
Strategic Insights for Stakeholders
Implications for Pharmaceutical Development
- The broad composition claims provide a foundation for developing various folate-targeted therapies.
- Method claims expand the use of these conjugates for different tumor types expressing folate receptor alpha.
- Potential patent challenges include demonstrating invalidity due to prior art or obviousness based on existing folate conjugates.
Licensing and Commercial Opportunities
- Array BioPharma has historically licensed this technology, indicating potential for out-licensing agreements.
- Competitive advantage derives from the specificity of targeting mechanisms and conjugate stability.
Regulatory and IP Considerations
- Patent term expiration was in 2020, allowing generic development under current US law.
- Future patent landscape expansions may involve second-generation conjugates or alternative receptor targets.
- Alignment with FDA guidance on targeted therapies enhances market acceptance.
Deep Dive: Claims Scope and Limitations
| Aspect |
Description |
Scope |
Limitation / Risk |
| Conjugate scope |
Folate derivative conjugated to specified drugs via linkers |
Broad coverage for all similar conjugates |
Challenges may arise if prior art shows similar structures |
| Method scope |
Therapeutic methods using these conjugates |
Includes all treatment protocols using the conjugates |
Must demonstrate novelty over prior art to avoid invalidation |
| Dosing and administration |
Various dosing regimens |
Potentially narrow; specific to embodiments |
Limitation if not explicitly claimed in broad claims |
Conclusion and Key Takeaways
- Broader Claim Scope: The '341 patent's composition and method claims are sufficiently broad to cover numerous folate-targeted chemotherapeutic conjugates and their clinical use, providing a strategic IP position.
- Patent Landscape: The patent family is dense, with related active patents focusing on conjugation chemistry, targeting precision, and specific therapeutic agents, establishing a strong foothold in the targeted cancer therapy niche.
- Market Impact: The patent's expiration in 2020 opens opportunities for generics and biosimilar development, although ongoing patent filings and licenses from array and competitors continue to shape the competitive landscape.
- Investment and Development Advice: Entities interested in folate receptor-targeted therapies should analyze this patent’s scope to ensure freedom to operate or to license innovator technologies, along with vigilance for related patent expirations.
FAQs
Q1: What is the primary therapeutic target of the '341 patent?
A1: The patent targets the folate receptor alpha, predominantly expressed on certain cancer cells, allowing for selective drug delivery.
Q2: How broad are the composition claims of US 6,740,341?
A2: They encompass a wide range of folate conjugates with various chemotherapeutic agents, linked through specified chemical linkers, covering multiple potential formulations.
Q3: Are there any active litigations involving this patent?
A3: No significant litigations are publicly recorded against the '341 patent, though licensing agreements are common.
Q4: How does this patent landscape influence development of new folate-targeted therapies?
A4: It provides a foundational IP base, but with patent expirations and ongoing patent filings, there's scope for innovation and alternative approaches.
Q5: When did the patent expire, and what does that imply for market competition?
A5: The patent expired in 2020, opening the market for generic development and reducing barriers for new entrants.
References
- U.S. Patent No. 6,740,341. "Method for treating cancer with folate receptor targeted compounds." 2004.
- Array BioPharma Inc. patent portfolio on folate receptor-targeted therapeutics.
- Patent and Trademark Office (USPTO). Public records and legal statuses.
- Industry reports on targeted cancer therapies, 2022–2023.
- FDA guidelines on targeted drug delivery systems, 2021.
This analysis aims to provide business professionals and patent strategists with a comprehensive understanding of US Patent 6,740,341, enabling well-informed decisions regarding patent landscape navigation, licensing strategies, and development pathways.
More… ↓
⤷ Start Trial
|
